FAQ: Kairos Pharma's ENV-105 Phase 2 Results for Advanced Prostate Cancer

What is ENV-105 and what does it treat?

ENV-105 (carotuximab) is Kairos Pharma’s lead antibody candidate that targets CD105, a protein identified as a key driver of resistance to cancer treatments. It’s currently in Phase 2 trials for metastatic castration-resistant prostate cancer and Phase 1 trials for lung cancer.

What were the key findings from the Phase 2 trial?

The interim results showed clinical benefit in 86% of patients treated with ENV-105 combined with apalutamide, with all responders remaining progression-free for at least four months and half beyond one year. Seven of nine evaluable patients experienced PSA reductions.

Why are these results significant for prostate cancer treatment?

These results are significant because they demonstrate the therapy’s potential to restore hormone responsiveness in advanced prostate cancer patients who have developed resistance to standard treatments, addressing a major unmet medical need.

How does ENV-105 work to fight cancer?

ENV-105 targets CD105, a protein that elevates in response to standard cancer therapy and causes resistance and disease relapse. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies.

Where were these results presented?

The interim efficacy data were presented at the European Society for Medical Oncology meeting in Berlin.

Who is conducting the clinical trial?

The randomized Phase 2 trial is led by Cedars-Sinai and partner institutions, and continues to enroll patients to further evaluate safety and long-term efficacy.

What is Kairos Pharma’s focus as a company?

Kairos Pharma is a clinical-stage biopharmaceutical company based in Los Angeles that develops innovative cancer therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer.

Where can I find more information about Kairos Pharma and this development?

The full press release is available at https://ibn.fm/1KEqw and the company’s newsroom is at https://ibn.fm/KAPA.

What is the current status of the ENV-105 clinical development program?

ENV-105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, with the Phase 2 trial continuing to enroll patients for further evaluation.